PFS - Merck garners Canadian approval for Keytruda in first-line gastroesophageal cancer
2024-04-19 12:03:30 ET
More on Merck
- Merck Earnings Preview: Not Much To Fear, Plenty To Look Forward To
- Merck: We Were Wrong, But The Exuberance Is Overly Done Here (Rating Upgrade)
- Merck: Better Times Ahead On Approvals And Outlook
- Moderna stock climbs 8% amid head/neck cancer vaccine data
- Morgan Stanley sees Fed rate cut fueling biotech stocks